[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612765":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":24,"locations":30,"responsibleParty":46,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Children's Hospital of Fudan University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"The patient is over 1 year old; for those who do not respond to conventional treatments (proton pump",null,[12,13],"Drug: Dupilumab - Standard Dose","Device: subcutaneous injection",[15,20],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Dupilumab - Standard Dose","Dose: For patients with weight ≥ 15kg but \\\u003C 30kg, take 200mg each time, every two weeks; for those with weight ≤ 30kg but \\\u003C 60kg, take 300mg each time, every two weeks; for those with weight ≥ 60kg, take 300mg each time, once a week.",[9],{"type":21,"name":22,"description":18,"armGroupLabels":23,"otherNames":10},"DEVICE","subcutaneous injection",[9],[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Ying Huang","CONTACT","021-64931727","yhuang815@163.com",[31],{"facility":32,"status":33,"city":34,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"201102","RECRUITING","Shanghai","China","CN",{"type":38,"coordinates":39},"Point",[40,41],121.45806,31.22222,{"lat":41,"lon":40},[44],{"name":45,"role":27,"phone":28,"phoneExt":10,"email":29},"Zhi-heng Huang",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Ying HUANG","Head of gastroenterology department","100612765","dupilumab-therapy-for-egids-100612765",false,"NCT07257835","Dupilumab Therapy for EGIDs","Dupilumab Therapy for Refractory Eosinophilic Gastrointestinal Disorders in Children","Inclusion Criteria:\n\n* Clinical diagnosis of Refractory Peptic Ulcers\n* with Refractory Eosinophilic Gastrointestinal Disorders\n\nExclusion Criteria:\n\n* with Active Helicobacter pylori infection at present.\n* with Inflammatory bowel disease\n* with Parasite infection\n* with Cancer","ALL","1 Year","18 Years",{"count":61,"type":62},20,"ESTIMATED","OBSERVATIONAL","This is a single-center observational study to investigate the efficacy and tolerability of dupilumab in children with refractory eosinophilic gastrointestinal disorders.",[66],"Eosinophilic Gastrointestinal Disorders (EGIDs)","2025-11-26",{"date":69,"type":70},"2025-12-02","ACTUAL",{"date":72,"type":70},"2025-01-01",{"date":74,"type":62},"2027-12-01",{"name":5,"class":6},1]